Stock Ratings / Health Care / RCUS / earnings

HCM (46) PGEN (35) PHVS (63) PBH (72) ⌘ Pro Terminal →

Arcus Biosciences Inc. (RCUS) Next Earnings Date & Expected ±12.5% Move

Q: When is RCUS's next earnings date?

Based on SEC filing cadence, Arcus Biosciences Inc. (RCUS)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is RCUS stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for RCUS, spanning a range between $16.28 and $20.94.

$18.61 +1.20% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Arcus Biosciences Inc. (RCUS) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.37B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RCUS)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$2.33 Expected Swing

MODEL EARNINGS SETUP GAUGE

RCUS Quantitative Pre-Earnings Setup: 35/100

Trailing EPS: $4.25 • YoY Revenue Growth: -35.3%

Model Bullish Setup (35/100)Model Risk Weight (65/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$33.0M	-$353.0M	-$484.0M	52%
FY 2024	2024-12-31	$51.0M	-$283.0M	-$176.0M	52%
FY 2023	2023-12-31	$37.0M	-$307.0M	-$306.0M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RCUS)

✓Walkthrough of RCUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RCUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.02%📐 HORIZONTAL RANGE

2026-10-30O $18.34H $18.90L $17.81C $18.61VOL 1.94M

RES: $31.39SUP: $16.70SMA50: $24.98SMA200: $24.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RCUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RCUS Butterfly Map → + Track RCUS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -35.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RCUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RCUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RCUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RCUS)

Health Care Rank #809 of 1016 ⚔️ HCM vs RCUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RCUS vs. HCM, PGEN, PHVS, PBH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Arcus Biosciences Inc. (RCUS) ranks #809 by composite RQD confidence (35/100, grade D-) and #229 by equity capitalization ($2.37B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with RCUS at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RCUS ACTIVE Arcus Biosciences Inc.	D-	35/100	—	—	-35.0%	+1.20%	$2.37B	Benchmark Subject
HCM HUTCHMED (China) Limited	D	46/100	5.2x	—	-2.5%	+2.03%	$2.37B	/hcm-vs-rcus →
PGEN Precigen Inc.	D-	35/100	—	—	-35.0%	+9.21%	$2.38B	/pgen-vs-rcus →
PHVS Pharvaris N.V.	C	63/100	—	—	—	+2.32%	$2.34B	/phvs-vs-rcus →
PBH Prestige Consumer Healthcare Inc.	B	72/100	12.1x	54.7%	13.8%	+2.01%	$2.31B	/pbh-vs-rcus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001724521

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arcus Biosciences Inc. (RCUS) reported GAAP revenue of $33.0M (-35.3% vs. FY2024 revenue of $51.0M , and -10.8% cumulative change since FY2023) , GAAP net income of -$353.0M, operating cash flow of -$482.0M, and free cash flow of -$484.0M (-175.0% YoY). On the balance sheet, RCUS closed FY2025 with $1.14B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.0M	-$353.0M	-$482.0M	-$484.0M	$1.14B	—
FY2024 (FY)	2024-12-31	$51.0M	-$283.0M	-$170.0M	-$176.0M	$1.15B	—
FY2023 (FY)	2023-12-31	$37.0M	-$307.0M	-$306.0M	-$306.0M	—	—

3. RCUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RCUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Arcus Biosciences Inc. (NYSE: RCUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $18.61 (+1.20% 1D, market cap $2.37B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RCUS ranks #809 in composite RQD confidence.

How does RCUS compare to HCM and PGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCUS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HCM (HUTCHMED (China) Limited) holds a D grade (46/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.37B) and PGEN (Precigen Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.38B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RCUS?

Per RCUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001724521), Arcus Biosciences Inc. generated $33.0M in revenue (-35.3% YoY), -$353.0M in net income, and -$484.0M in free cash flow against $1.14B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RCUS trading relative to its 50-day, 200-day, and 52-week technical levels?

RCUS last traded at $18.61 (+1.20% on volume of 1,665,799 shares), positioning the stock -25.50% below its 50-day simple moving average ($24.98) and -24.53% below its 200-day simple moving average ($24.66). Across its 52-week range of $17.43 to $31.74, RCUS sits at the 8.2% percentile with a 14-day RSI of 30.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($16.28 to $20.94).

RCUS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is RCUS's next earnings date?

Based on SEC filing cadence, Arcus Biosciences Inc. (RCUS)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is RCUS stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for RCUS, spanning a range between $16.28 and $20.94.

Direct Sub-Reports: RCUS RQD Cockpit RCUS 12M Forecast RCUS Earnings & Move RCUS Dividends & DRIP RCUS Insiders & 13F RCUS Whale Options RCUS Profit Sankey RCUS News & Why